Enzymotec Launches Next Generation Krill Oil Product - K•REAL® Gold
June 06 2017 - 7:30AM
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid ingredients and medical
foods, today announced the launch of K•REAL® Gold, its next
generation krill oil product. K•REAL® Gold is immediately available
for purchase and represents the first launch in a line of new krill
oil products that are under development.
K•REAL® Gold is highly concentrated in Omega-3
levels. It is rich in beneficial omega-3 fatty acids and
Astaxanthin, produced using Enzymotec’s proprietary, cutting-edge
MSO® 2.0 technology, which creates a high quality “T-free”1,2 and
oxidation resistant1,3 product with an additional “low-sodium”
offering in the European Union.
Avner Avissara, Vice President of Nutrition at
Enzymotec, commented, “The introduction of K•REAL® Gold, using our
cutting-edge MSO® 2.0 technology, enables Enzymotec to offer the
market a unique product of unprecedented quality. This launch
reaffirms Enzymotec’s commitment to delivering the highest quality
krill products to remain competitive in a crowded krill oil market.
We are excited to continue to pioneer products with exceptional
freshness and superb oxidation resistance1,3, as well as the
assurance that our products are T-free1,2 and in the EU, low-sodium
as well."
Notes to Editors
1These statements have not been evaluated/
authorized by the Commission in accordance with Regulation (EC)
1924/2006 on nutrition and health claims made on foods.
2”T-free” refers to Trimethylamine N-oxide
(TMAO) and Trimethylamine (TMA) free. Limit of detection of both
TMAO and TMA is 1mgN/100g measured by Conway and Byrne’s
micro-diffusion method (Conway & O’Malley, Microdiffusion
Methods. Biochem, 36, 656-661(1942)).
3Relative to competing krill oil products. Based
on results from in-vitro stomach model conducted by Enzymotec,
where the levels of MDA of krill oils from various producers were
tested.
Forward Looking Statements
This press release may contain forward-looking
statements related to Enzymotec’s business strategy, outlook,
objectives, plans, intentions or goals. The words "may," "will,"
"should," "plans," "explores," "expects," "anticipates,"
"continue," "estimate," "project," "intend," and similar
expressions, identify forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, but their
absence does not mean that the statement is not forward-looking.
These statements are not guarantees of future performance and are
subject to certain risks, uncertainties, and assumptions that are
difficult to predict. Actual results could differ materially.
Enzymotec expressly disclaims any obligation or undertaking to
update or revise any forward-looking statement contained herein to
reflect any change in the company's expectations with regard
thereto or any change in events, conditions or circumstances upon
which any statement is based.
About Enzymotec
Ltd.
Enzymotec is a leading global supplier of
specialty lipid-based products and solutions. The Company develops,
manufactures and markets innovative bio-active lipid ingredients,
as well as final products, based on sophisticated processes and
technologies.
For more information, visit
http://www.enzymotec.com
Contact:
The Ruth Group
Tram Bui / Alexander Lobo
(646) 536-7035 / 7037
tbui@theruthgroup.com
alobo@theruthgroup.com
Ingredient Communications
Richard Clarke
+44 1293 886291 (office) / +44 7766 256176 (mobile)
richard@ingredientcommunications.com
@ingredientcomms
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024